498 related articles for article (PubMed ID: 12171531)
1. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
2. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies.
Pearson DA; Lister-James J; McBride WJ; Wilson DM; Martel LJ; Civitello ER; Taylor JE; Moyer BR; Dean RT
J Med Chem; 1996 Mar; 39(7):1361-71. PubMed ID: 8691466
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs for diagnosis and treatment of cancer.
Weckbecker G; Raulf F; Stolz B; Bruns C
Pharmacol Ther; 1993 Nov; 60(2):245-64. PubMed ID: 7912834
[TBL] [Abstract][Full Text] [Related]
8. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
13. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
17. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
Rubino M; Di Stasio GD; Bodei L; Papi S; Rocca PA; Ferrari ME; Fodor CI; Bagnardi V; Frassoni S; Mei R; Fazio N; Ceci F; Grana CM
Endocrine; 2024 May; 84(2):704-710. PubMed ID: 38324106
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
Krassas GE; Dumas A; Pontikides N; Kaltsas T
Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
[TBL] [Abstract][Full Text] [Related]
19. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]